BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sirtex Medical Reports 4Q Sales Growth of 23%


7/22/2011 10:27:33 AM

Sydney, Australia 22 July 2011; Sirtex Medical Limited (ASX:SRX) today said sales of SIR-Spheres® microspheres, it’s targeted radioactive treatment for inoperable liver cancer, grew 23% in the fourth quarter of the 2011 Financial Year compared with the same quarter last year. Full year dose sales grew 19.3% compared to a 14% growth the year before.

Dose sales are a key performance measure and Sirtex has now reported 28 consecutive quarters of positive dose sales growth.

Sirtex Chief Executive Gilman Wong said, “This unbroken line of steady growth reflects the growing awareness and confidence among the international medical community about the positive clinical outcomes for patients treated with SIR-Spheres® microspheres. The results demonstrate our strategies to grow the business are working and we are very encouraged that more people are able to benefit from this potentially life improving therapy.”

Compared to the previous corresponding periods US sales grew 30.9% for the quarter and 19.3% for the year, Europe grew 17.7% for the quarter and 24.5% for the full year whilst Asia Pacific sales declined 5.4% in the quarter but grew 3.1% for the year. The Asia Pacific result reflects the transition following the appointment of a new Regional Head and a reconfiguration of Asian sales efforts in key markets to ensure long-term growth.

Current sales of SIR-Spheres® microspheres represent less than 1% of the addressable global market of people diagnosed annually worldwide with liver cancer. Approximately 20,000 doses of SIR-Spheres® microspheres have now been supplied to treat liver cancer patients at more than 400 medical centres worldwide to date.

Andrew Geddes

City Public Relations

Suite 1, Level 2

507 Kent Street

Sydney NSW 2000

Ph: (02) 8916 4848

Mobile: 0408 677 734



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES